Of carcinomas, all but one (41/42, 98%) were MMR‐deficient by microsatellite instability or immunohistochemical analysis, and 86% (36/42) showed loss of heterozygosity or somatic variants of MMR genes as putative second hits. Here, MRC1 is linked to carcinoma.